B cells in SLE. Different biological drugs for different pathogenic mechanisms [PDF]
, 2007 Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major players. Recently,
Carsetti, Rita +3 more
core +1 more source
Advanced NanoBiomed Research, EarlyView.This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari +5 more
wiley +1 more source
Expression and clinical significance of NGAL/NGALR in lupus nephritis
Linchuang shenzangbing zazhi, 2017 Objective To investigate the expression and clinical significance of NGAL/NGALR in lupus nephritis( LN). Methods Eighty-four patients with systemic lupus erythematosus( SLE) were selected in this study,and divided into LN group and non-LN group.
ZENG Xing-ruo +4 more
doaj
AB0652 HISTOLOGICAL RENAL FEATURES AND CYTOKINES ASSESSMENT AS POSSIBLE BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS [PDF]
, 2023 Valentina Varriano +6 more
openalex +1 more source
Identifying chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knockout mice [PDF]
, 2004 Chemokines, in concert with cytokines and adhesion molecules, play multiple roles in local and systemic immune responses. In the kidney, the temporal and spatial expression of chemokines correlates with local renal damage and accumulation of chemokine ...
Abdi R +34 more
core +1 more source
Lupus nephritis: challenges and progress.
Current Opinion in Rheumatology, 2019 PURPOSE OF REVIEW The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to guide individualized therapeutic decisions. This review
A. Davidson, C. Aranow, M. Mackay
semanticscholar +1 more source
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Arthritis &Rheumatology, EarlyView.Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
#2898 UNMET NEEDS AND POOR LONG-TERM RENAL OUTCOMES IN EUROPEAN PATIENTS WITH LUPUS NEPHRITIS [PDF]
, 2023 Jonathan Barratt +5 more
openalex +1 more source
Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort [PDF]
, 2015 Objectives. The anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70–98% of patients test positive. We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the ...
Alessandri, Cristiano +9 more
core +1 more source
T cell–specific STAT3 deficiency abrogates lupus nephritis
Lupus, 2019 Signal transducer and activator of transcription (STAT) 3 is a regulator of T-cell responses to external stimuli, such as pro-inflammatory cytokines and chemokines.
N. Yoshida +4 more
semanticscholar +1 more source